DiaMedica Therapeutics (NASDAQ:DMAC) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

DiaMedica Therapeutics (NASDAQ:DMAC) released its earnings results on Wednesday. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02), FiscalAI reports.

DiaMedica Therapeutics Stock Up 4.3%

NASDAQ DMAC traded up $0.27 on Wednesday, hitting $6.52. The stock had a trading volume of 184,771 shares, compared to its average volume of 168,615. DiaMedica Therapeutics has a one year low of $3.47 and a one year high of $10.42. The stock has a market cap of $351.30 million, a price-to-earnings ratio of -9.31 and a beta of 0.99. The company’s 50-day moving average is $6.92 and its two-hundred day moving average is $7.56.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. bought a new stake in shares of DiaMedica Therapeutics during the third quarter valued at about $27,000. Bank of America Corp DE lifted its stake in shares of DiaMedica Therapeutics by 3,710.3% in the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after acquiring an additional 8,274 shares during the period. Truvestments Capital LLC lifted its stake in shares of DiaMedica Therapeutics by 112.3% in the 4th quarter. Truvestments Capital LLC now owns 9,849 shares of the company’s stock worth $78,000 after acquiring an additional 5,210 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of DiaMedica Therapeutics in the 4th quarter worth approximately $89,000. Finally, Jump Financial LLC acquired a new stake in shares of DiaMedica Therapeutics in the 4th quarter worth approximately $89,000. Institutional investors own 10.12% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Monday, April 20th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.33.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.